查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587831

中枢神经系统治疗市场规模、份额和趋势分析报告：按疾病、药物类别、分销管道、地区、细分市场预测，2025-2030

Central Nervous System Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Drug Class (Anticonvulsants, CNS Stimulants), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

中枢神经系统治疗市场的成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球中枢神经系统药物市场规模将达到2.546亿美元，2025年至2030年复合年增长率为10.4%。

在预测期内，大量未满足的医疗需求和政府减轻疾病负担的措施正在推动中枢神经系统（CNS）治疗市场的发展。据世界卫生组织称，忧郁症和焦虑症每年对全球经济造成超过 1 兆美元的损失，预计到 2030 年，全球心理健康病例的增加将导致经济损失增加 16 兆美元。

该市场未来具有强劲的成长机会，主要企业正在采取各种行销策略来巩固自己的地位，包括新产品开拓、合作伙伴关係、地理扩张、併购和新产品核可。 2020年2月，百健（Biogen）宣布投资 Sangamo 的锌指平台，用于开发阿兹海默症和其他神经系统疾病的治疗方法。同样，该公司与 Ionis Pharmaceuticals 达成协议，开发可应用于多种神经系统疾病的候选药物。

百健 (Biogen)、H. Lundbeck A/S、礼来公司 (Eli Lilly and Company) 等领先製药公司推出的强大研发线产品预计将在预测期内加速市场成长。其他製药公司也积极开发新治疗方法，并投入大量资金开发治疗中枢神经系统疾病的有效疗法。

许多处于后期开发的药物用于治疗神经退化性疾病，例如阿兹海默症、多发性硬化症、帕金森氏症和肌萎缩侧索硬化症。 aducanumab、brexpiprozole、evobrutinib 和 solanezumab 等候选药物可能在未来五到八年内商业化，用于治疗各种神经退化性疾病适应症。除了神经退化性疾病外，偏头痛、思觉失调症和癫痫是主要的中枢神经系统适应症，潜在的候选药物正在研发中。

预计癌症领域在预测期内将呈现最快的成长速度。患病率上升、死亡率高以及对有效治疗的需求不断增长预计将推动中枢神经系统治疗市场的成长。根据美国国家癌症美国估计，2020 年美国新患者23,890 例，死亡病例 18,020 例。

製药公司采用产品开拓、併购和联盟等策略来加强其市场地位。例如，Biogen 与 Ionis Pharmaceuticals、Atalanta Therapeutics 和 Sangamo Therapeutics 达成协议，开发针对中枢神经系统各种疾病的新疗法。同样，2020 年 1 月，CNS Pharmaceuticals 与 MD 安德森癌症中心签订了授权合约，开发 WP1244，一种旨在穿越血脑障壁的 DNA粘合剂，以探索脑肿瘤的潜在治疗方法。

中枢神经系统治疗市场报告亮点

  • 由于阿兹海默症、帕金森氏症、多发性硬化症等盛行率不断增加，神经退化性疾病预计在预测期内将以 11.5% 的复合年增长率增长最快。
  • 预计中枢神经系统癌症领域在预测期内将呈现最快的成长速度。对有效治疗的需求不断增长预计将推动这一领域的发展。
  • 由于治疗率的提高和医疗基础设施的改善，预计亚太地区在未来几年将出现最快的成长。
  • 北美地区因其在该地区的高知名度和更好的赎回场景而在2024年占据了大部分市场份额。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章中枢神经系统治疗市场的变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章中枢神经系统治疗市场：疾病业务分析

  • 2024年及2030年疾病市场占有率
  • 疾病细分仪表板
  • 2018-2030 年按疾病分類的市场规模、预测与趋势分析
  • 神经血管疾病
  • 中枢神经系统创伤
  • 心理健康
  • 神经退化性疾病
  • 感染疾病
  • 中枢神经系统癌症
  • 其他的

第五章中枢神经系统治疗市场：药物类别的商业分析

  • 2024 年及 2030 年药品类别市场占有率
  • 药品类别细分仪表板
  • 2018-2030 年按药物类别分類的市场规模、预测与趋势分析
  • 麻醉剂
  • 抗惊厥药
  • 止吐药
  • 中枢神经系统兴奋剂
  • 止痛药
  • 其他的

第六章中枢神经系统治疗市场：通路的业务分析

  • 2024 年及 2030 年分销通路市场占有率
  • 分销通路细分仪表板
  • 2018-2030 年按分销管道分類的市场规模、预测与趋势分析
  • 医院药房
  • 零售药房
  • 其他的

第七章中枢神经系统治疗市场：按疾病、药物类别和分销管道进行的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 参与企业概况
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • Biogen
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Merck &Co., Inc.
    • Astra Zeneca
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd
    • Johnson &Johnson Services, Inc.
    • Pfizer Inc.
Product Code: GVR-1-68038-516-8

Central Nervous System Therapeutic Market Growth & Trends:

The global central nervous system therapeutics market size is expected to reach USD 254.6 million by 2030, registering a CAGR of 10.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. High unmet medical needs and government initiatives to reduce the disease burden are driving the market for central nervous system (CNS) therapeutic over the forecast period. According to WHO, the global economy loses due to depression and anxiety is more than USD 1 trillion per year and rising patient base of mental health globally is expected to increase the economy loses by USD 16 trillion in 2030.

The market holds strong future growth opportunities and major players are adopting different marketing strategies such as new product development, collaborations, geographic expansion, mergers and acquisitions, and new product approval, to strengthen their positions. In February 2020, Biogen announced the investment in Sangamo's zinc finger platform to develop therapies for Alzheimer's disease and other neurological diseases. Similarly, the company has an agreement with Ionis Pharmaceutical for the development of drug candidates applicable across a wide range of neurological diseases.

Presence of strong pipeline products by major pharmaceutical companies such as Biogen, H. Lundbeck A/S, Eli Lilly and Company, and others are expected to accelerate market growth over the forecast period. Besides, other pharmaceutical companies are also actively involved in the development of novel therapies and investing heavily to develop effective therapeutics for the treatment of CNS associated diseases.

Most of the late phase development drugs are for the treatment of neurodegenerative disorders such as Alzheimer's disease, multiple sclerosis, Parkinson's disease, and amyotrophic lateral sclerosis. The drug candidates such as aducanumab, brexpiprozole, evobrutinib, solanezumab are some of the potential drugs that could be commercialized in the next five to eight years for the treatment of various indication of neurodegenerative disorders. Apart from neurodegenerative diseases, migraine, schizophrenia, and epilepsy are the major CNS disease indications that have potential drug candidates in pipeline.

The cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing prevalence, high mortality rate, and rising demand for effective treatment are expected to fuel the growth of the market for CNS therapeutic. According to National Cancer Institute estimates, the number of new cases of CNS cancers was 23,890 whereas the number of deaths was 18,020 in the U.S. in 2020.

Pharmaceutical companies are adopting strategies such as product development, merger and acquisition, and collaboration to strengthen their position in market. For instance, Biogen has signed agreements with Ionis Pharmaceuticals, Atalanta Therapeutics, and Sangamo Therapeutics to develop novel therapeutics for the treatment of different disease indications of the central nervous system. Similarly, in January 2020, the CNS Pharmaceuticals has entered into a licensing agreement with MD Anderson Cancer Center to investigate WP1244, a designed DNA-binding agent to cross the blood-brain barriers for the potential treatment of brain cancers.

Central Nervous System Therapeutic Market Report Highlights:

  • Neurodegenerative diseases are projected to witness the fastest growth with a CAGR of 11.5% over the forecast period, owing to the increasing prevalence of conditions such as Alzheimer's, Parkinson's, and multiple sclerosis.
  • The CNS cancer segment is expected to witness the fastest growth rate over the forecast period. Increasing demand for effective treatment is expected to drive the segment
  • In Asia Pacific, the market is estimated to witness the fastest growth over the coming years owing to the increase in treatment rate and betterment of healthcare infrastructure in the region
  • North America held a majority of share in 2024 due to high awareness level in the region and better reimbursement scenario

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug Class
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Central Nervous System Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Central Nervous System Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 4.4. Neurovascular Diseases
    • 4.4.1. Neurovascular Diseases Market, 2018 - 2030 (USD Million)
  • 4.5. CNS Trauma
    • 4.5.1. CNS Trauma Market, 2018 - 2030 (USD Million)
  • 4.6. Mental Health
    • 4.6.1. Mental Health Market, 2018 - 2030 (USD Million)
    • 4.6.2. Anxiety Disorders
      • 4.6.2.1. Anxiety Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.3. Epilepsy
      • 4.6.3.1. Epilepsy Market, 2018 - 2030 (USD Million)
    • 4.6.4. Mood Disorders
      • 4.6.4.1. Mood Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.5. Psychotic Disorders
      • 4.6.5.1. Psychotic Disorders Market, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market, 2018 - 2030 (USD Million)
  • 4.7. Neurodegenerative Diseases
    • 4.7.1. Neurodegenerative Diseases Market, 2018 - 2030 (USD Million)
    • 4.7.2. Alzheimer's Disease
      • 4.7.2.1. Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.3. Parkinsosn's Disease
      • 4.7.3.1. Parkinsosn's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.4. Multiple Sclerosis
      • 4.7.4.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 4.7.5. Huntington's Disease
      • 4.7.5.1. Huntington's Disease Market, 2018 - 2030 (USD Million)
    • 4.7.6. Amytrophic Lateral Sclerosis
      • 4.7.6.1. Amytrophic Lateral Sclerosis Market, 2018 - 2030 (USD Million)
    • 4.7.7. Others
      • 4.7.7.1. Others Market, 2018 - 2030 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 4.9. CNS Cancer
    • 4.9.1. CNS Cancer Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Central Nervous System Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Anesthetics
    • 5.4.1. Anesthetics Market, 2018 - 2030 (USD Million)
  • 5.5. Anticonvulsants
    • 5.5.1. Anticonvulsants Market, 2018 - 2030 (USD Million)
  • 5.6. Antiemetics
    • 5.6.1. Antiemetics Market, 2018 - 2030 (USD Million)
  • 5.7. CNS Stimulants
    • 5.7.1. CNS Stimulants Market, 2018 - 2030 (USD Million)
  • 5.8. Pain Relievers
    • 5.8.1. Pain Relievers Market, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Central Nervous System Therapeutics Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Central Nervous System Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Drug Class, Distribution Channel

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Central Nervous System Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Central Nervous System Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Biogen
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Otsuka Pharmaceutical Co., Ltd.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Eli Lilly and Company
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Merck & Co., Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Astra Zeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Takeda Pharmaceutical Company Limited
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Novartis AG
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Johnson & Johnson Services, Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Pfizer Inc.
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global central nervous system therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 6. Global central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7. North America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 8. North America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 9. North America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 10. North America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11. U.S. central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 12. U.S. central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 13. U.S. Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 14. Canada central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 15. Canada central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 16. Canada central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Mexico central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Mexico central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 19. Mexico central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20. Europe central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 21. Europe central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Europe central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 23. Europe central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24. UK central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 25. UK central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 26. UK Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 27. Germany central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 28. Germany central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 29. Germany central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. France central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 31. France central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 32. France Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33. Italy central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 34. Italy central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 35. Italy central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36. Spain central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 37. Spain central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 38. Spain central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39. Norway central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 40. Norway central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 41. Norway Central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Denmark central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Denmark central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 44. Denmark central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45. Sweden central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 46. Sweden central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 47. Sweden central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48. Asia Pacific central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 49. Asia Pacific central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 50. Asia Pacific central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 51. Asia Pacific central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52. Japan central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 53. Japan central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 54. Japan central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 55. China central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 56. China central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 57. China central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. India central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 59. India central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 60. India central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61. Australia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 62. Australia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 63. Australia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 64. South Korea central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 65. South Korea central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 66. South Korea central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. Thailand central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 68. Thailand central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 69. Thailand central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70. Latin America central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 71. Latin America central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Latin America central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 73. Latin America central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74. Brazil central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 75. Brazil central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 76. Brazil central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77. Argentina central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 78. Argentina central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 79. Argentina central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 80. Middle East & Africa Central nervous system therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 81. Middle East & Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 82. Middle East & Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 83. Middle East & Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 84. South Africa central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 85. South Africa central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 86. South Africa central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Saudi Arabia central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Saudi Arabia central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 89. Saudi Arabia central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90. UAE central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 91. UAE central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 92. UAE central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 93. Kuwait central nervous system therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 94. Kuwait central nervous system therapeutics market, by drug class, 2018 - 2030 (USD Million)
  • Table 95. Kuwait central nervous system therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Central nervous system therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Disease and drug class (USD Million)
  • Fig. 10 Distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Central nervous system therapeutics market dynamics
  • Fig. 13 Central nervous system therapeutics market: Porter's five forces analysis
  • Fig. 14 Central nervous system therapeutics market: PESTLE analysis
  • Fig. 15 Central nervous system therapeutics market Disease segment dashboard
  • Fig. 16 Central nervous system therapeutics market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Neurovascular diseases market, 2018 - 2030 (USD Million)
  • Fig. 18 CNS trauma market, 2018 - 2030 (USD Million)
  • Fig. 19 Mental health market, 2018 - 2030 (USD Million)
  • Fig. 20 Anxiety disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 22 Mood disorders market, 2018 - 2030 (USD Million)
  • Fig. 23 Psychotic disorders market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Neurodegenerative diseases market, 2018 - 2030 (USD Million)
  • Fig. 26 Alzheimer's disease market, 2018 - 2030 (USD Million)
  • Fig. 27 Parkinsosn's disease market, 2018 - 2030 (USD Million)
  • Fig. 28 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 29 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 30 Amytrophic lateral sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 31 Others market, 2018 - 2030 (USD Million)
  • Fig. 32 Infectious diseases market, 2018 - 2030 (USD Million)
  • Fig. 33 CNS cancer market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Central nervous system therapeutics market: Drug class segment dashboard
  • Fig. 36 Central nervous system therapeutics market: Drug class market share analysis, 2024 & 2030
  • Fig. 37 Anesthetics market, 2018 - 2030 (USD Million)
  • Fig. 38 Anticonvulsants market, 2018 - 2030 (USD Million)
  • Fig. 39 Antiemetics market, 2018 - 2030 (USD Million)
  • Fig. 40 CNS stimulants market, 2018 - 2030 (USD Million)
  • Fig. 41 Pain relievers market, 2018 - 2030 (USD Million)
  • Fig. 42 Others market, 2018 - 2030 (USD Million)
  • Fig. 43 Central nervous system therapeutics market: Distribution channel segment dashboard
  • Fig. 44 Central nervous system therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 45 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 46 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 47 Others market, 2018 - 2030 (USD Million)
  • Fig. 48 Central nervous system therapeutics market revenue, by region
  • Fig. 49 Regional marketplace: Key takeaways
  • Fig. 50 Regional marketplace: Key takeaways
  • Fig. 51 North America central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. country dynamics
  • Fig. 53 U.S. central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Canada country dynamics
  • Fig. 55 Canada central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico country dynamics
  • Fig. 57 Mexico central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Europe central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 59 UK country dynamics
  • Fig. 60 UK central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 61 Germany country dynamics
  • Fig. 62 Germany central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 63 France country dynamics
  • Fig. 64 France central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 65 Italy country dynamics
  • Fig. 66 Italy central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 67 Spain country dynamics
  • Fig. 68 Spain central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Norway country dynamics
  • Fig. 70 Norway central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 Sweden country dynamics
  • Fig. 72 Sweden central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 Denmark country dynamics
  • Fig. 74 Denmark central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 Asia Pacific central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 76 Japan country dynamics
  • Fig. 77 Japan central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 78 China country dynamics
  • Fig. 79 China central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 80 India country dynamics
  • Fig. 81 India central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Australia country dynamics
  • Fig. 83 Australia central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 South Korea country dynamics
  • Fig. 85 South Korea central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 Thailand country dynamics
  • Fig. 87 Thailand central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 88 Latin America central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 89 Brazil country dynamics
  • Fig. 90 Brazil central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 91 Argentina country dynamics
  • Fig. 92 Argentina central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 93 MEA central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 94 South Africa country dynamics
  • Fig. 95 South Africa central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 96 Saudi Arabia country dynamics
  • Fig. 97 Saudi Arabia central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 98 UAE country dynamics
  • Fig. 99 UAE central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 100 Kuwait country dynamics
  • Fig. 101 Kuwait central nervous system therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 102 Company categorization
  • Fig. 103 Company market position analysis
  • Fig. 104 Strategic framework